Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02417142 · ClinicalTrials.gov registry record · Phase 4
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
A Phase 4 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
NCT02417142 is a Phase 4 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 70 participants.
The verdict
NCT02417142, a Phase 4 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine exenatide's effects on negative symptoms and cognition.
Interventions
- DRUG Placebo
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-09 |
| Est. Completion | 2020-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02417142
The ClinicalTrials.gov registry entry for NCT02417142 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02417142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02417142 about?
NCT02417142 is a clinical study titled "Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia". This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine exenatide's effects on negative symptoms and cognition.
What is the current status of trial NCT02417142?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2014-09. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02417142?
The interventions under investigation include: Placebo (DRUG), Exenatide (DRUG).
Who is sponsoring clinical trial NCT02417142?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.